Boston Scientific To Study Complex Drug-Eluting Stent Use; Taxus Complaints Surface
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is projecting worldwide Taxus revenue of $1.7 bil-$2.2 bil. for 2004, building on early 70% share claimed in the U.S. drug-eluting stent market. The paclitaxel-eluting stent's delivery platform has been subject to roughly 40 complaints since its launch in early March.